Moleculin Biotech, Inc. (MBRX) News
Filter MBRX News Items
MBRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MBRX News Highlights
- MBRX's 30 day story count now stands at 3.
- Over the past 10 days, the trend for MBRX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about MBRX are DRUG and PRE.
Latest MBRX News From Around the Web
Below are the latest news stories about MOLECULIN BIOTECH INC that investors may wish to consider to help them evaluate MBRX as an investment opportunity.
Moleculin Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-MarketMoleculin Biotech, Inc. (NASDAQ: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor and certain of the Company's executive officers and directors to purchase 7,044,836 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offerin |
Here's Why We're A Bit Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Moleculin Presents Positive Interim Data from Phase 1B/2 Clinical Trial in AML at Meeting with KOL's in Conjunction with ASH Annual MeetingMoleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced the presentation of preliminary efficacy findings from the Company's ongoing European Phase 1B/2 clinical trial evaluating Annamycin for the treatment of acute myeloid leukemia or AML (MB-106) to key opinion leaders and current investigators at a meeting held in conjuncti |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time for a breakdown of the biggest pre-market stock movers as we check out all of the hottest news on Thursday morning! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayIt's time to dive into the biggest pre-market stock movers for Tuesday morning with all of the latest news you need to know today! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayPre-market stock movers are a hot topic on Wednesday as we check out all of the biggest movements happening this morning! |
Moleculin Biotech, Inc. (NASDAQ:MBRX) Q3 2023 Earnings Call TranscriptMoleculin Biotech, Inc. (NASDAQ:MBRX) Q3 2023 Earnings Call Transcript November 13, 2023 Operator: Greetings, and welcome to the Moleculin Biotech Third Quarter 2023 Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded. At this time, I’d like to turn the call over to Jenene Thomas, Investor Relations. Thank you. You […] |
Moleculin (MBRX) Up 7% on Upbeat Updates From Annamycin StudiesMoleculin (MBRX) announces positive interim data from its early-mid-stage studies of Annamycin in blood and lung cancer indications, along with encouraging third-quarter results. The stock rises 7%. |
Moleculin Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 MonthsMoleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today provided a preliminary update on recent clinical activity and expected near term milestones across its clinical development pipeline in its quarterly filing with the Securities and Exchange Commission. |
Moleculin Reports Third Quarter 2023 Financial ResultsMoleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today reported its financial results for the quarter ended September 30, 2023. As previously announced, the Company will host a conference call and live audio webcast, today, November 13, 2023, at 8:30 AM ET (details below). |